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Dysgenesis(RD).
Survivors had at least 1y follow up. OS at 1y was 88% (63/74).
Grade 2-4 aGVHD was seen in 19%, Grade 3-4 aGVHD in 8% &
cGVHD in 17% by 1y. A 2nd HCT was needed in 6 patients by
1y. Of these, 5/6 survived. Initially 5 received no condition-
ing/serotherapy vs. 1 who received RIC/MAC (p ¼ 0.005).
Leaky SCID/Omenn had similar 1y OS to typical SCID (86% vs.
92%; p ¼ 0.212; Fig 1). Both patients with RD died. By donor
type 1y OS was 100% for MRD; 94% for MMRD; 84% for URD &
73% for UCB. Mortality was similar irrespective of condi-
tioning: 13% no conditioning/serotherapy; 18% RIC; 15%MAC.
Mortality was due to infection [CMV (3), EBV PTLD (1), RSV/
PCP (1), Trichosporon (1) & Enterococcus (1)] and, seen only
in MAC, HCT complications [VOD (3), encephalopathy (1)].
At 1y, median CD3 chimerism was >98% regardless of con-
ditioning. Use of RIC/MAC vs no conditioning/serotherapy
was associated with better median lineage speciﬁc donor
chimerism in CD19 (99% vs 10%; p ¼ 0.005) & myeloid cells
(97% vs 1%; p <0.001) & trended toward freedom from IVIG
(43% vs. 17%; p ¼ 0.056). In typical SCID median CD4 counts
were higher in those receiving RIC/MAC (1482 vs 878; p ¼
0.022; Fig 2). In cohort-wide comparison of HCT with vs
without conditioning, median CD4 count (1345 vs 855), %
CD45RA (43 vs. 40) & PHA response (both 100%) were not
signiﬁcantly different.
Survival of patients with typical SCID & leaky SCID/Omenn
after HCT was high, but problems remained. Deaths were
most commonly related to infection, but a 3rd were attrib-
utable to conditioning toxicities, in particular VODwithMAC.
This emphasizes need to minimize busulfan use. Condition-
ing improved certain aspects of immune reconstitution at 1y
& decreased need for 2nd HCT. GVHD affected w1 in 5 in-
fants. Future efforts to decrease GVHD & establish safer
chemotherapy exposure in very young infants requiring
conditioning are needed to improve outcomes. Longer-term
follow-up of these patients will identify factors that impact
late effects & quality of life post HCT for SCID.
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The last two decades have seen Donor Lymphocyte Infusion
(DLI) emerge as a treatment option for disease relapse
following allogeneic stem cell transplant. Reviewing the
literature reveals a great degree of variability in how DLI is
performed. One trend is to use G-CSF-mobilized stem cells
instead of conventionally collected stem cells. It is alsounclear whether the type of cells utilized, fresh versus cry-
opreserved, impacts the DLI efﬁcacy.
We identiﬁed all patients who underwent DLI for persistent
or relapsed disease at the Temple BMT Unit between 7/1993
and 12/2013. We determined response to DLI per standard
criteria to calculate event free survival (EFS) and overall
survival (OS), post-DLI. Correlative calculations were con-
ducted between DLI and pre-transplant conditioning
regimen [Myeloablative vs. Non-Myeloablative], DLI condi-
tioning regimen [if any], # of CD3+ cells infused, absence or
presence of post-DLI GVHD and interval between original
transplant and disease progression with respect to EFS
and OS.
We identiﬁed 63 patients who received DLI for persistent or
relapsed disease. Median F/U was 5.4 years (range 0.03-
11.88). The OS was similar between the cryopreserved and
fresh cells groups [median OS for cryopreserved¼0.39 yrs,
median OS for fresh¼0.32 yrs; p¼0.79] [Fig 1A]. Type of pre-
transplant conditioning [myeloablative versus non-myelo-
ablative] had no impact on OS [for myeloablative, p¼0.52; for
non-myeloablative, p¼0.12]. The EFS was similar between
the two groups [median EFS for cryopreserved¼0.41 yrs,
median EFS for fresh¼0.42 yrs; p¼0.43] [Fig 1B]. Analysis
based upon pre-transplant conditioning resulted in similar
EFS values [for myeloablative, p¼0.98; for non-myelo-
ablative, p¼0.14]. Presence or absence of GVHD post-DLI had
no impact on OS or EFS [n¼55, p¼0.5]. The dose of CD3+
cells infused for each DLI [median dose ¼ 5.00E7cells,
range¼2.00E6-5.20E8] had no correlation with OS [p¼0.13]
or EFS [p¼0.3]. The interval between original transplant and
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range¼0.09-9.01yrs] had a signiﬁcant impact on OS [p<0.01]
and EFS [p<0.01]. Notably, treatment with any chemo-
therapy prior to receiving a DLI did not signiﬁcantly impact
OS [p¼0.22] or EFS [p¼0.54].
Our analysis reveals no difference in OS or EFS between the
use of fresh or cryopreserved cells for DLI. There is a trend to
favor fresh cell DLI in patients who have undergone a non-
myeloablative transplant. Our study conﬁrmed previous
observations that a greater interval between original trans-
plant and relapse correlates with greater DLI success.We also
highlight that in the setting of relapsed disease, pretreat-
ment with chemotherapy did not impact post-DLI OS or EFS.
In conclusion, selected patients can achieve long term sur-
vival with DLI for post-transplant relapse though the overall
outcomes remain dismal.Figure 1. Time to transplant from preliminary search
Figure 2. Cumulative incidence probability of transplant with an adult unre-
lated donor with CBU transplant as a competing risk415
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African American (AFA) patients are an underserved race
group in bone marrow transplant due to their diverse HLA,
limited number of potential unrelated donors (URD) and low
URD availability rates. Newly entered AFA patients who had
Be The Match Registry searches of intermediate difﬁculty
were enrolled in this blind randomized study to determine if
proactive URD contact and HLA typing would (1) increase
patient transplant rates (2) increase selection of an URD over
a cord blood unit (CBU).
We examined incoming patients from Feb to Oct of 2013 to
identify and enroll a subset of AFA searches who had 10
potential 8/8 URD with HapLogic allele matching prediction
of 31% or zero 8/8 with 10 7/8 URD with matching pre-
diction of 76%. Searches were randomized 1:1 into two
arms; 182 to intervention and 178 to no intervention. In the
intervention arm, HLA specialists reviewed 182 patient
searches and selected 2473 URD for contact to conﬁrm
availability with 591 available URD HLA typed (up to 20 URD/
patient). Patient searches were excluded from the study if
they had “unproductive”URD search results (i.e. no URDwith
at least a 2% chance of being 7/8) or had “very productive”
URD search results (i.e. 11 URD with 31% prediction of
being an 8/8 or zero potential 8/8 URD with 10 URD with
75% prediction of being a 7/8). URD were high-resolution
typed at HLA-A, B, C, DRB1 and DQB1, and the transplant
center was notiﬁed when an available 7/8 or better matched
URD was identiﬁed for consideration. Patient cases were
followed for URD or CBU transplant endpoints up to 1 year
post initial search submission.
Descriptive statistics for the two randomized arms were
similar in patient age, disease (malignant vs non-malignant),
and URD search productivity. 217matched and available URD
notiﬁcations were sent to transplant centers on behalf of 115
patients. Although not achieving statistical signiﬁcance,
intervention patients progressed to transplant 20% of the
time vs. 15% in the non-intervention group at 1 year (Figure
1) and transplanted more oftenwith an URD over a CBU, 63%
vs. 48%, respectively. At 1 year, the intervention group pro-
gressed to URD transplant in 12% of cases compared to 7% in
the non-intervention group (Figure 2) and CBU transplant in
7% of intervention cases vs. 8% in the non-intervention group.AFA searches not meeting the inclusion criteria for study
randomization were also examined. Very productive poten-
tial 8/8 URD searches resulted in transplant 27% of the time
(88% chose an URD) and searches containing zero 8/8 URD
with many potential 7/8 URD resulted in transplant 19% of
the time (44% chose an URD). Patients that had zero potential
7/8 donors with at least 2% likelihood to match only went to
transplant 2% of the time.
Additional registry URD contact and HLA typing efforts for
challenging AFA patient searches may clarify the search op-
tions available and assist transplant decision making.416
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Aim: Infection is the leading cause of non-relapse mortality
(NRM) in allo-HSCT. A community respiratory virus infection
(RVI) screening programwas instituted at our center from 5/
2010 in order to prevent nosocomial infection, assist in
